Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism)

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1043)

Abstract

Since the early 1990s, it has been recognized that testosterone (T) levels are lower in men with type 2 diabetes mellitus (T2DM) compared with nondiabetic men (controls). Hypogonadism has been reported in approximately 50% of men with T2DM with robust correlations with measures of obesity, such as waist circumference and body mass index (BMI). In longitudinal studies, hypogonadism has been identified as a predictor of incident T2DM. Experimental withdrawal of T led to acute decreased insulin sensitivity, which can be reversed by normalization of T concentrations. Androgen deprivation therapy, commonly used in men with advanced prostate cancer, increases the risk of incident T2DM significantly.

While short-term studies of T therapy in hypogonadal men with T2DM show only minor effects, long-term administration of T leads to meaningful and sustained improvements of glycemic control with parallel reductions in body weight and waist circumference. The more insulin-resistant and obese a patient is at the time of initiation of T therapy, the more improvements are noted. The observed effects are likely mediated by the increase in lean body mass invariably achieved by T therapy, as well as the improvement in energy and motivation, referred to as the psychotropic effects of T. As recommended by various guidelines, measuring T levels and, if indicated, restoring men’s T levels into the normal physiological range can have a substantial impact on ameliorating T2DM in hypogonadal men.

References

  1. Alemán-Mateo, H., López Teros, M. T., Ramírez, C. F. A., & Astiazarán-García, H. (2014). Association between insulin resistance and low relative appendicular skeletal muscle mass: Evidence from a cohort study in community-dwelling older men and women participants. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 69(7), 871–877.CrossRefPubMedGoogle Scholar
  2. Andersson, B., Mårin, P., Lissner, L., Vermeulen, A., & Björntorp, P. (1994). Testosterone concentrations in women and men with NIDDM. Diabetes Care, 17(5), 405–411.CrossRefPubMedGoogle Scholar
  3. Antonio, L., Wu, F. C. W., O’Neill, T. W., Pye, S. R., Carter, E. L., Finn, J. D., Rutter, M. K., Laurent, M. R., Huhtaniemi, I. T., Han, T. S., Lean, M. E. J., Keevil, B. G., Pendleton, N., Rastrelli, G., Forti, G., Bartfai, G., Casanueva, F. F., Kula, K., Punab, M., Giwercman, A., Claessens, F., Decallonne, B., Vanderschueren, D., & the EMAS Study Group. (2015). The Journal of Clinical Endocrinology and Metabolism, 100(4), 1396–1404.CrossRefPubMedGoogle Scholar
  4. Arthur, R., Rohrmann, S., Møller, H., Selvin, E., Dobs, A. S., Kanarek, N., Nelson, W., Platz, E. A., & Van Hemelrijck, M. (2017). Pre-diabetes and serum sex steroid hormones among US men. Andrologia, 5(1), 49–57.CrossRefGoogle Scholar
  5. Atlantis, E., Martin, S. A., Haren, M. T., Taylor, A. W., Wittert, G. A., & Members of the Florey Adelaide Male Ageing Study. (2009). Inverse associations between muscle mass, strength, and the metabolic syndrome. Metabolism, Clinical and Experimental, 58(7), 1013–1022.CrossRefGoogle Scholar
  6. Atlantis, E., Fahey, P., Martin, S., O’Loughlin, P., Taylor, A. W., Adams, R. J., Shi, Z., & Wittert, G. (2016). Predictive value of serum testosterone for type 2 diabetes risk assessment in men. BMC Endocrine Disorders, 16, 26.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Aversa, A., Bruzziches, R., Francomano, D., Rosano, G., Isidori, A. M., Lenzi, A., & Spera, G. (2010). Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. The Journal of Sexual Medicine, 7(10), 3495–3503.CrossRefPubMedGoogle Scholar
  8. Basaria, S. (2008). Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. Journal of Andrology, 29(5), 534–539.CrossRefPubMedGoogle Scholar
  9. Basaria, S., Muller, D. C., Carducci, M. A., Egan, J., & Dobs, A. S. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106(3), 581–588.CrossRefPubMedGoogle Scholar
  10. Boyanov, M. A., Boneva, Z., & Christov, V. G. (2003). Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The Aging Male, 6(1), 1–7.CrossRefPubMedGoogle Scholar
  11. Brand, J. S., Wareham, N. J., Dowsett, M., Folkerd, E., van der Schouw, Y. T., Luben, R. N., & Khaw, K.-T. (2011). Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men. Clinical Endocrinology, 74(5), 572–578.CrossRefPubMedGoogle Scholar
  12. Buchwald, H., & Oien, D. M. (2009). Metabolic/ bariatric surgery worldwide 2008. Obesity Surgery, 19(12), 1605–1611.CrossRefPubMedGoogle Scholar
  13. Buysschaert, M., Medina, J. L., Bergman, M., Shah, A., & Lonier, J. (2015). Prediabetes and associated disorders. Endocrinology, 48(2), 371–393.Google Scholar
  14. Caminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & GMC, R. (2009). Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. Journal of the American College of Cardiology, 54(10), 919–927.CrossRefPubMedGoogle Scholar
  15. Colangelo, L. A., Ouyang, P., Liu, K., Kopp, P., Hill Golden, S., Dobs, A. S., Szklo, M., Vaidya, D., Cushman, M., & Gapstur, S. M. (2009). Association of endogenous sex hormones with diabetes and impaired fasting glucose in men. Diabetes Care, 32(6), 1049–1051.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Cornoldi, A., Caminiti, G., Marazzi, G., Vitale, C., Patrizi, R., Volterrani, M., Miceli, M., Fini, M., Spera, G., & Rosano, G. (2010). Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. International Journal of Cardiology, 142(1), 50–55.CrossRefPubMedGoogle Scholar
  17. Corona, G., Monami, M., Rastrelli, G., Aversa, A., Tishova, Y., Saad, F., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011). Testosterone and metabolic syndrome: A meta-analysis study. The Journal of Sexual Medicine, 8(1), 272–283.CrossRefPubMedGoogle Scholar
  18. Corona, G., Rastrelli, G., Balercia, G., Lotti, F., Sforza, A., Monami, M., Forti, G., Mannucci, E., & Maggi, M. (2012). Hormonal association and sexual dysfunction in patients with impaired fasting glucose: A cross-sectional and longitudinal study. The Journal of Sexual Medicine, 9(6), 1669–1680.CrossRefPubMedGoogle Scholar
  19. Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004). Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 89(11), 5462–5468.CrossRefPubMedGoogle Scholar
  20. Dhindsa, S., Miller, M. G., McWhirter, C. L., Mager, D. E., Ghanim, H., Chaudhuri, A., & Dandona, P. (2010). Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care, 33(6), 1186–1192.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Dhindsa, S., Ghanim, H., Batra, M., Kuhadiya, N. D., Abuaysheh, S., Sandhu, S., Green, K., Makdissi, A., Hejna, J., Chaudhuri, A., Punyanitya, M., & Dandona, P. (2016). Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care, 39(1), 82–91.CrossRefPubMedGoogle Scholar
  22. Dockery, F., Bulpitt, C. J., Agarwal, S., Donaldson, M., & Rajkumar, C. (2003). Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science, 104(2), 195–201.CrossRefPubMedGoogle Scholar
  23. Dominguez, L. J., & Barbagallo, M. (2007). The cardiometabolic syndrome and sarcopenic obesity in older persons. Journal of the Cardiometabolic Syndrome, 2(3), 183–189.CrossRefPubMedGoogle Scholar
  24. Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008). Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men. Journal of the American Medical Association, 299(1), 39–52.PubMedGoogle Scholar
  25. Fornari, R., Francomano, D., Greco, E. A., Marocco, C., Lubrano, C., Wannenes, F., Papa, V., Bimonte, V. M., Donini, L. M., Lenzi, A., Aversa, A., & Migliaccio, S. (2015). Lean mass in obese adult subjects correlates with higher levels of vitamin D, insulin sensitivity and lower inflammation. Journal of Endocrinological Investigation, 38(3), 367–372.CrossRefPubMedGoogle Scholar
  26. Gianatti, E. J., Dupuis, P., Hoermann, R., Strauss, B. J., Wentworth, J. M., Zajac, J. D., & Grossmann, M. (2014). Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: A randomized controlled trial. Diabetes Care, 37(8), 2098–2107.CrossRefPubMedGoogle Scholar
  27. Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010). Diabetes and cancer: A consensus report. Diabetes Care, 33(7), 1674–1685.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Goodman-Gruen, D., & Barrett-Connor, E. (2000). Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care, 23(7), 912–918.CrossRefPubMedGoogle Scholar
  29. Gopal, R. A., Bothra, N., Acharya, S. V., Ganesh, H. K., Bandgar, T. R., Menon, P. S., & Shah, N. S. (2010). Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocrine Practice, 16(4), 570–576.CrossRefPubMedGoogle Scholar
  30. Grossmann, M. (2011). Low testosterone in men with type 2 diabetes: Significance and treatment. The Journal of Clinical Endocrinology and Metabolism, 96(8), 2341–2353.CrossRefPubMedGoogle Scholar
  31. Grossmann, M. (2014). Testosterone and glucose metabolism in men: current concepts and controversies. The Journal of Endocrinology, 220(3), R37–R55.CrossRefPubMedGoogle Scholar
  32. Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008). Low testosterone levels are common and associated with insulin resistance in men with diabetes. The Journal of Clinical Endocrinology and Metabolism, 93(5), 1834–1840.CrossRefPubMedGoogle Scholar
  33. Grossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B. (2015). Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: A systematic review and meta-analysis of randomized controlled clinical trials. Clinical Endocrinology, 83(3), 344–351.CrossRefPubMedGoogle Scholar
  34. Gummesson, A., Nyman, E., Knutsson, M., & Karpefors, M. (2017). Effect of weight reduction on hemoglobin A1c in weight loss trials of type 2 diabetes patients. Diabetes, Obesity and Metabolism, Published online May 22, 2017.  https://doi.org/10.1111/dom.12948.
  35. Hackett, G. I. (2010). Testosterone and type 2 diabetes: The forgotten link. Prim Care Cardiovascular Journal, 3(4), 190–192.Google Scholar
  36. Hackett, G. I., Cole, N. S., Deshpande, A. A., Popple, M. D., Kennedy, D., & Wilkinson, P. (2009). Biochemical hypogonadism in men with type 2 diabetes in primary care practice. British Journal of Diabetes Vascular Disease, 9(5), 226–231.CrossRefGoogle Scholar
  37. Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013). Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. The Journal of Sexual Medicine, 10(6), 1612–1627.CrossRefPubMedGoogle Scholar
  38. Hackett, G., Heald, A. H., Sinclair, A., Jones, P. W., Strange, R. C., & Ramachandran, S. (2016). Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. International Journal of Clinical Practice, 70(3), 244–253.CrossRefPubMedGoogle Scholar
  39. Hackett, G., Jones, P. W., Strange, R. C., & Ramachandran, S. (2017). Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World Journal of Diabetes, 8(3), 104–111.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Haffner, S. M., Shaten, J., Stern, M. P., Smith, G. D., & Kuller, L. (1996). Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. American Journal of Epidemiology, 143(9), 889–897.CrossRefPubMedGoogle Scholar
  41. Haider, A., Yassin, A., Saad, F., & Shabsigh, R. (2007). Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. The Aging Male, 10(4), 189–196.CrossRefGoogle Scholar
  42. Haider, A., Yassin, A., Doros, G., & Saad, F. (2014). Effects of long-term testosterone therapy on patients with “diabesity”: Results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International Journal of Endocrinology, 1–15. Article ID 683515.Google Scholar
  43. Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017). No progression from prediabetes to type 2 diabetes (T2DM) in 45 hypogonadal men receiving testosterone therapy (TTh) for up to 9 years: Real-life data from a registry study. Diabetologia, 60(Suppl. 1), S395. (abstract).Google Scholar
  44. Hamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J., Lim-Joon, D., Bolton, D., Zajac, J. D., & Grossmann, M. (2011). Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clinical Endocrinology, 74(3), 377–383.CrossRefPubMedGoogle Scholar
  45. Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009). Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of Andrology, 30(6), 726–733.CrossRefPubMedGoogle Scholar
  46. Ho, C.-H., Yu, H.-J., Wang, C.-Y., Jaw, F.-S., Hsieh, J.-T., Liao, W.-C., Pu, Y.-S., & Liu, S.-P. (2013). Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One, 8(9), e74173.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Holmboe, S. A., Jensen, T. K., Linneberg, A., Scheike, T., Thuesen, B. H., Skakkebaek, N. E., Juul, A., & Andersson, A.-M. (2016). Low testosterone: A risk marker rather than a risk factor for type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 101(9), 3180–3190.CrossRefPubMedGoogle Scholar
  48. Hoyos, C. M., Yee, B. J., Phillips, C. L., Machan, E. A., Grunstein, R. R., & Liu, P. Y. (2012). Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: A randomised placebo-controlled trial. European Journal of Endocrinology, 167(4), 531–541.CrossRefPubMedGoogle Scholar
  49. Inaba, M., Otani, Y., Nishimura, K., Takaha, N., Okuyama, A., Koga, M., Azuma, J., Kawase, I., & Kasayama, S. (2005). Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism, Clinical and Experimental, 54(1), 55–59.CrossRefGoogle Scholar
  50. Jockenhövel, F., Minnemann, T., Schubert, M., Freude, S., Hübler, D., Schumann, C., Christoph, A., Gooren, L., & Ernst, M. (2009). Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. The Aging Male, 12(4), 113–118.CrossRefPubMedGoogle Scholar
  51. Jones, T. H. (2007). Hypogonadism in men with type 2 diabetes. Practical Diabetes International, 24(5), 269–277.CrossRefGoogle Scholar
  52. Jones, T. H. (2010). Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. Journal of Diabetes, 2(3), 146–156.CrossRefPubMedGoogle Scholar
  53. Jones, T. H. (2014). Comment on Gianatti et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: A randomized controlled trial. Diabetes Care, 37(12), e267–e268.CrossRefPubMedGoogle Scholar
  54. Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Martin Morales, A., Volterrani, M., Yellowlees, A., Howell, J. D., Channer, K. S., & the TIMES2 Investigators. (2011). Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care, 34(4), 828–837.CrossRefPubMedPubMedCentralGoogle Scholar
  55. Joyce, K. E., Biggs, M. L., Djoussé, L., Ix, J. H., Kizer, J. R., Siscovick, D. S., Shores, M. M., Matsumoto, A. M., & Mukamal, K. J. (2017). Testosterone, dihydrotestosterone, sex hormone–binding globulin, and incident diabetes among older men: The cardiovascular health study. The Journal of Clinical Endocrinology and Metabolism, 102(1), 33–39.PubMedGoogle Scholar
  56. Kalinchenko, S. Y., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J. G., Giltay, E. J., & Saad, F. (2010). Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clinical Endocrinology, 73(5), 602–612.CrossRefPubMedGoogle Scholar
  57. Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006). Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 154(6), 899–906.CrossRefPubMedGoogle Scholar
  58. Kapoor, D., Aldred, H., Clark, S., Channer, K. S., & Jones, T. H. (2007). Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care, 30(4), 911–917.CrossRefPubMedGoogle Scholar
  59. Keating, N. L., O’Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24(27), 4448–4456.CrossRefPubMedGoogle Scholar
  60. Kelleher, S., Conway, A. J., & Handelsman, D. J. (2004). Blood testosterone threshold for androgen deficiency symptoms. The Journal of Clinical Endocrinology and Metabolism, 89(8), 3813–3817.CrossRefPubMedGoogle Scholar
  61. Kelly, D. M., & Jones, T. H. (2013a). Testosterone: A metabolic hormone in health and disease. The Journal of Endocrinology, 217(3), R25–R45.CrossRefPubMedGoogle Scholar
  62. Kelly, D. M., & Jones, T. H. (2013b). Testosterone: A vascular hormone in health and disease. The Journal of Endocrinology, 217(3), R47–R71.CrossRefPubMedGoogle Scholar
  63. Kelly, D. M., & Jones, T. H. (2014). Testosterone and cardiovascular risk in men. In R. Granata & J. Isgaard (Eds.), Cardiovascular issues in endocrinology, Front Horm Res (Vol. 43, pp. 1–20). Basel: Karger.Google Scholar
  64. Kelly, D. M., & Jones, T. H. (2015). Testosterone and obesity. Obesity Reviews, 16(7), 581–601.CrossRefPubMedGoogle Scholar
  65. Kim, C., & Halter, J. B. (2014). Endogenous sex hormones, metabolic syndrome, and diabetes in men and women. Current Cardiology Reports, 16(4), 467.CrossRefPubMedPubMedCentralGoogle Scholar
  66. Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004). Testosterone and sex hormone–binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 27(5), 1036–1041.CrossRefPubMedGoogle Scholar
  67. Lakshman, K. M., Bhasin, S., & Araujo, A. B. (2010). Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 65(5), 503–509.CrossRefPubMedGoogle Scholar
  68. Li, Q., Chen, L., Yang, Z., Ye, Z., Huang, Y., He, M., Zhang, S., Fend, X., Gong, W., Zhang, Z., Zhao, W., Liu, C., Qu, S., & Hu, R. (2012). Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index < 35 kg/m2. Diabetes, Obesity & Metabolism, 14(3), 262–270.CrossRefGoogle Scholar
  69. López Teros, M. T., Ramírez, C. F. A., & Alemán-Mateo, H. (2015). Hyperinsulinemia is associated with the loss of appendicular skeletal muscle mass at 4.6 year follow-up in older men and women. Clinical Nutrition, 34(5), 931–936.CrossRefPubMedGoogle Scholar
  70. Magnussen, L. V., Glintborg, D., Hermann, P., Hougaard, D. M., Højlund, K., & Andersen, M. (2016). Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. Diabetes, Obesity & Metabolism, 18(10), 980–989.CrossRefGoogle Scholar
  71. Malkin, C. J., Pugh, P. J., West, J. N., van Beek, E. J. R., Jones, T. H., & Channer, K. S. (2006). Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. European Heart Journal, 27(1), 57–64.CrossRefPubMedGoogle Scholar
  72. Maric, C. (2009). Sex, diabetes and the kidney. American Journal of Physiology. Renal Physiology, 296(4), F680–F688.CrossRefPubMedPubMedCentralGoogle Scholar
  73. Mårin, P., & Arver, S. (1998). Androgens and abdominal obesity. Baillière’s Clinical Endocrinology and Metabolism, 12(3), 441–451.CrossRefPubMedGoogle Scholar
  74. Mårin, P., Andersson, B., Ottosson, M., Olbe, L., Chowdhury, B., Kvist, H., Holm, G., Sjöström, L., & Björntorp, P. (1992a). The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism, 41(11), 1242–1248.CrossRefPubMedGoogle Scholar
  75. Mårin, P., Holmäng, S., Jönsson, L., Sjöström, L., Kvist, H., Holm, G., Lindstedt, G., & Björntorp, P. (1992b). The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders, 16(12), 991–997.PubMedGoogle Scholar
  76. Mårin, P., Krotkiewski, M., & Björntorp, P. (1992c). Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. The European Journal of Medicine, 1(6), 329–336.PubMedGoogle Scholar
  77. Mårin, P., Holmäng, S., Gustafsson, C., Jönsson, L., Kvist, H., Elander, A., Eldh, J., Sjöström, L., Holm, G., & Björntorp, P. (1993). Androgen treatment of abdominally obese men. Obesity Research, 1(4), 245–251.CrossRefPubMedGoogle Scholar
  78. Mauvais-Jarvis, F. (2016a). Role of sex steroids in β cell function, growth, and survival. Trends in Endocrinology and Metabolism, 27(12), 844–855.CrossRefPubMedPubMedCentralGoogle Scholar
  79. Mauvais-Jarvis, F. (2016b). Androgen-deprivation therapy and pancreatic β-cell dysfunction in men. The Journal of Diabetic Complications, 30(3), 389–390.CrossRefGoogle Scholar
  80. Morgentaler, A., Miner, M. M., Caliber, M., Guay, A. T., Khera, M., & Traish, A. M. (2015). Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clinic Proceedings, 90(2), 224–251.CrossRefPubMedGoogle Scholar
  81. Morgentaler, A., Zitzmann, M., Traish, A. M., Fox, A. W., Jones, T. H., Maggi, M., Arver, S., Aversa, A., Chan, J. C. N., Dobs, A. S., Hackett, G. I., Hellstrom, W. J., Lim, P., Lunenfeld, B., Mskhalaya, G., Schulman, C. C., & Torres, L. O. (2016). Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutions. Mayo Clinic Proceedings, 91(7), 881–896.CrossRefPubMedGoogle Scholar
  82. Muller, M., Grobbee, D. E., den Tonkelaar, I., Lamberts, S. W. J., & van der Schouw, Y. T. (2005). Endogenous sex kormones and metabolic syndrome in aging men. The Journal of Clinical Endocrinology and Metabolism, 90(5), 2618–2623.CrossRefPubMedGoogle Scholar
  83. Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013). Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169(6), 725–733.CrossRefPubMedGoogle Scholar
  84. Naharci, M. I., Pinar, M., Bolu, E., & Olgun, A. (2007). Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocrine Practice, 13(6), 629–635.CrossRefPubMedGoogle Scholar
  85. Nair, K. S., Rizza, R. A., O’Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., Cobelli, C., Toffolo, G., Dalla Man, C., Tindall, D. J., Melton, L. J., II, Smith, G. E., Khosla, S., & Jensen, M. D. (2006). DHEA in elderly women and DHEA or testosterone in elderly men. New English Journal of Medicine, 355(16), 1647–1659.CrossRefGoogle Scholar
  86. Navarro, G., Allard, C., Xu, W., & Mauvais-Jarvis, F. (2015). The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity, 23(4), 713–719.CrossRefPubMedPubMedCentralGoogle Scholar
  87. Navarro, G., Xu, W., Jacobson, D. A., Wicksteed, B., Allard, C., Zhang, G., De Gendt, K., Kim, S. H., Wu, H., Zhang, H., Verhoeven, G., Katzenellenbogen, J. A., & Mauvais-Jarvis, F. (2016). Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metabolism, 23(5), 837–851.CrossRefPubMedPubMedCentralGoogle Scholar
  88. Ng Tang Fui, M., Prendergast, L. A., Dupuis, P., Raval, M., Strauss, B. J., Zajac, J. D., & Grossmann, M. (2016). Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: A randomised controlled trial. BMC Medicine, 14(1), 153.CrossRefPubMedPubMedCentralGoogle Scholar
  89. Ng Tang Fui, M., Hoermann, R., Zajac, J. D., & Grossmann, M. (2017). The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment. Clinical Endocrinology, 87(4), 336–343. Published online May 31, 2017.Google Scholar
  90. O’Connell, M. D. L., Roberts, S. A., Srinivas-Shankar, U., Tajar, A., Connolly, M. J., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2011). Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? The Journal of Clinical Endocrinology and Metabolism, 96(2), 454–458.CrossRefPubMedGoogle Scholar
  91. Oh, J.-Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002). Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo Study. Diabetes Care, 25(1), 55–60.CrossRefPubMedGoogle Scholar
  92. Pasquali, R. (2006). Obesity and androgens: Facts and perspectives. Fertility and Sterility, 85(5), 1319–1340.CrossRefPubMedGoogle Scholar
  93. Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – Long term results of phase III RTOG 85-31. International Journal of Radiation Oncology, Biology, Physics, 61(5), 1285–1290.CrossRefPubMedGoogle Scholar
  94. Pitteloud, N., Hardin, M., Dwyer, A. A., Valassi, E., Yialamas, M. A., Elahi, D., & Hayes, F. J. (2005a). Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. The Journal of Clinical Endocrinology and Metabolism, 90(5), 2636–2641.CrossRefPubMedGoogle Scholar
  95. Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K.-F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., & Hayes, F. J. (2005b). Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care, 28(7), 1636–1642.CrossRefPubMedGoogle Scholar
  96. Rabijewski, M., Papierska, L., & Piatkewicz, P. (2014). The prevalence of prediabetes in population of Polish men with late-onset hypogonadism. The Aging Male, 17(3), 141–146.CrossRefPubMedGoogle Scholar
  97. Rabijewski, M., Papierska, L., Kuczerowski, R., & Piatkiewicz, P. (2015). Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population. The Aging Male, 18(1), 16–21.CrossRefPubMedGoogle Scholar
  98. Ramachandran, S., Hackett, G. I., & Strange, R. C. (2017). Hypogonadism in men with diabetes: Should testosterone replacement therapy be based on evidence based testosterone levels and lifetime risk reduction? Edorium Journal of Biochemistry, 2, 1–3.Google Scholar
  99. Rao, P. M., Kelly, D. M., & Jones, T. H. (2013). Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews. Endocrinology, 9(8), 479–493.CrossRefPubMedGoogle Scholar
  100. Report of the expert committee on the diagnosis and classification of diabetes mellitus. (1997). Diabetes Care, 20(7), 1183–1197.Google Scholar
  101. Saad, F., Haider, A., Doros, G., & Traish, A. (2013). Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity, 21(10), 1975–1981.CrossRefPubMedGoogle Scholar
  102. Saad, F., Haider, A., Yassin, A., Doros, G., & Traish, A. (2015). Prevention of progression from prediabetes to diabetes in 109 hypogonadal men treated with testosterone for up to 8 years. Diabetologia, 58(Suppl. 1), S317–S318. (abstract).Google Scholar
  103. Saad, F., Haider, A., Haider, K. S., Doros, G., & Traish, A. (2016a). Type 2 diabetes (T2DM) and mortality in hypogonadal men improve upon long-term treatment with injectable testosterone undecanoate (TU): A controlled registry study. Diabetologia, 59(Suppl. 1), S184. (abstract).Google Scholar
  104. Saad, F., Yassin, A., Doros, G., & Haider, A. (2016b). Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: Observational data from two registry studies. International Journal of Obesity, 40(1), 162–170.CrossRefPubMedGoogle Scholar
  105. Saad, F., Yassin, D., Dorsos, G., & Yassin, A. (2017). Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate injections (TU) for up to 12 years. Diabetes, 66(Suppl. 1), A305. (abstract).Google Scholar
  106. Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., Litwin, M. S., & the Urologic Diseases in America Project. (2007). Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer, 110(7), 1493–1500.CrossRefPubMedGoogle Scholar
  107. Salminen, M., Vahlberg, T., Räihä, I., Niskanen, L., Kivelä, S. L., & Iriala, K. (2015). Sex hormones and the risk of type 2 diabetes mellitus: A 9-year follow up among elderly men in Finland. Geriatrics & Gerontology International, 15(5), 559–564.CrossRefGoogle Scholar
  108. Saylor, P. J., & Smith, M. R. (2009). Metabolic complications of androgen deprivation therapy for prostate cancer. The Journal of Urology, 181(5), 1998–2008.CrossRefPubMedPubMedCentralGoogle Scholar
  109. Schipf, S., Haring, R., Friedrich, N., Nauck, M., Lau, K., Alte, D., Stang, A., Völzke, H., & Wallaschofski, H. (2011). Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: Results from the Study of Health in Pomerania (SHIP). The Aging Male, 14(3), 168–175.CrossRefPubMedGoogle Scholar
  110. Schroeder, E. T., Zheng, L., Ong, M. D., Martinez, C., Flores, C., Stewart, Y., Azen, C., & Sattler, F. R. (2004). Effects of androgen therapy on adipose tissue and metabolism in older men. The Journal of Clinical Endocrinology and Metabolism, 89(10), 4863–4872.Google Scholar
  111. Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990). Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism, 39(9), 897–910.CrossRefPubMedGoogle Scholar
  112. Selvin, E., Feinleib, M., Zhang, L., Rohrmann, S., Rifai, N., Nelson, W. G., Dobs, A., Basaria, S., Golden, S. H., & Platz, E. A. (2007). Androgens and diabetes in men. Diabetes Care, 30(2), 234–238.CrossRefPubMedGoogle Scholar
  113. Shin, J. Y., Park, E. K., Park, B. J., Shim, J. Y., & Lee, H. R. (2012). High-normal glucose levels in non-diabetic and pre-diabetic men are associated with decreased testosterone levels. Korean Journal of Family Medicine, 33(3), 152–156.CrossRefPubMedPubMedCentralGoogle Scholar
  114. Shores, M. M., Smith, N. L., Forsberg, C. W., Anawalt, B. D., & Matsumoto, A. M. (2012). Testosterone treatment and mortality in men with low testosterone levels. The Journal of Clinical Endocrinology and Metabolism, 97(6), 2050–2058.CrossRefPubMedGoogle Scholar
  115. Sinclair, M., Grossmann, M., Hoermann, R., Angus, P. W., & Gow, P. J. (2016). Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. Journal of Hepatology, 65(5), 906–913.CrossRefPubMedGoogle Scholar
  116. Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockroft, J. R., Scanlon, M. F., & Davies, J. S. (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 86(9), 4261–4267.CrossRefPubMedGoogle Scholar
  117. Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 87(2), 599–603.CrossRefPubMedGoogle Scholar
  118. Smith, M. R., Lee, H., & Nathan, D. M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 91(4), 1305–1308.CrossRefPubMedGoogle Scholar
  119. Snyder, P. J., Cunningham, G. R., Matsumoto, A. M., Stephen-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., Ensrud, K. E., Lewis, C. E., Farrar, J. T., Cella, D., Rosen, R. C., Pahor, M., Crandall, J. P., Molitch, M. E., Cifelli, D., Dougar, D., Fluharty, L., Resnick, S. M., Storer, T. W., Anton, S., Basaria, S., Diem, S. J., Mohler, E. R., III, Parsons, J. K., Wenger, N. K., Zeldow, B., Landis, J. R., & Ellenberg SS for the Testosterone Trials Investigators. (2016). Effects of testosterone in older men. The New England Journal of Medicine, 374(7), 611–624.CrossRefPubMedPubMedCentralGoogle Scholar
  120. Srikanthan, P., & Karlamangla, A. S. (2011). Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the Third National Health and Nutrition Examination Survey. The Journal of Clinical Endocrinology and Metabolism, 96(9), 2898–2903.CrossRefPubMedGoogle Scholar
  121. Srikanthan, P., Hevener, A. L., & Karlamangla, A. S. (2010). Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: Findings from the National Health and Nutrition Examination Survey III. PLoS One, 5(5), e10805.CrossRefPubMedPubMedCentralGoogle Scholar
  122. Stellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000). Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men. Diabetes Care, 23(4), 490–494.CrossRefPubMedGoogle Scholar
  123. Svartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008). Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. International Journal of Impotence Research, 20(4), 378–387.CrossRefPubMedGoogle Scholar
  124. Tibblin, G., Adlerberth, A., Lindstedt, G., & Björntorp, P. (1996). The pituitary-gonadal axis and health in elderly men: A study of men born in 1913. Diabetes, 45(11), 1605–1609.CrossRefPubMedGoogle Scholar
  125. Tomar, R., Dhindsa, S., Chaudhuri, A., Mohanty, P., Garg, R., & Dandona, P. (2006). Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care, 29(5), 1120–1122.CrossRefPubMedGoogle Scholar
  126. Tong, S.-F., Ng, C.-J., Lee, B.-C., Lee, V. K. M., Khoo, E.-M., Lee, E.-G., & Tan, H.-M. (2012). Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: A double blind randomized controlled trial. Asian Journal of Andrology, 14(4), 604–611.CrossRefPubMedPubMedCentralGoogle Scholar
  127. Traish, A. M. (2014). Adverse health effects of testosterone deficiency (TD) in men. Steroids, 88, 106–116.CrossRefPubMedGoogle Scholar
  128. Traish, A. M. (2016). Testosterone therapy in men with testosterone deficiency: Are the benefits and cardiovascular risks real or imagined? American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 311(3), R566–R573.Google Scholar
  129. Traish, A. M., Haider, A., Doros, G., & Saad, F. (2014). Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: An observational, long-term registry study. International Journal of Clinicial Practice, 68(3), 314–329.Google Scholar
  130. Traish, A. M., Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017). Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: A real-life observational registry study setting comparing treated and untreated (control) groups. Journal of Cardiovascular Pharmacology and Therapeutics, Published online February 9, 2017.  https://doi.org/10.1177/1074248417691136.
  131. Tsai, E. C., Matsumoto, A. M., Fujimoto, W. Y., & Boyko, E. J. (2004). Association of bioavailable, free, and total testosterone with insulin resistance. Diabetes Care, 27(4), 861–868.CrossRefPubMedGoogle Scholar
  132. Tsai, H. K., D’Amico, A. V., Sadetsky, N., Chen, M. H., & Carroll, P. R. (2007). Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute, 99(20), 1516–1524.CrossRefPubMedGoogle Scholar
  133. Tsujimura, A. (2013). The relationship between testosterone deficiency and men’s health. World Journal of Mens Health, 31(2), 126–135.CrossRefGoogle Scholar
  134. Vermeulen, A., Kaufman, J. M., Deslypere, J. P., & Thomas, G. (1993). Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. The Journal of Clinical Endocrinology and Metabolism, 76(5), 1140–1146.PubMedGoogle Scholar
  135. Vikan, T., Schirmer, H., Njølstad, I., & Svartberg, J. (2010). Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. European Journal of Endocrinology, 162(4), 747–754.CrossRefPubMedGoogle Scholar
  136. Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004). Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 89(5), 2085–2098.CrossRefPubMedGoogle Scholar
  137. Wu, X.-y., Mao, J.-f., Lu, S.-y., Zhang, Q., & Shi, Y.-F. (2009). Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients. Chinese Medical Journal, 122(23), 2846–2850.PubMedGoogle Scholar
  138. Xia, J. W., Tan, S. J., Zhang, X. L., Jun, T., Sun, X. K., & Ling, W. (2015). Correlation of serum testosterone with insulin resistance in elderly male type 2 diabetes mellitus patients with osteoporosis. Journal of Diabetes Investigation, 6(5), 548–552.CrossRefPubMedPubMedCentralGoogle Scholar
  139. Xu, W., Niu, T., Xu, B., Navarro, G., Schipma, M. J., & Mauvais-Jarvis, F. (2017). Androgen receptor-deficient islet β-cells exhibit alteration in genetic markers of insulin secretion and inflammation. A transcriptome analysis in the male mouse. The Journal of Diabetic Complications, 31(5), 787–795.CrossRefGoogle Scholar
  140. Yassin, A., Almehmadi, Y., Saad, F., Doros, G., & Gooren, L. (2016a). Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal middle-aged and elderly men. Clinical Endocrinology, 84(1), 107–114.CrossRefPubMedGoogle Scholar
  141. Yassin, A., Nettleship, J. E., Talib, R. A., Almehmadi, Y., & Doros, G. (2016b). Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. The Aging Male, 19(1), 64–69.CrossRefPubMedGoogle Scholar
  142. Yeap, B. B., Chubb, S. A. P., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., & Norman, P. E. (2009). Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: The health in men study. European Journal of Endocrinology, 161(4), 591–598.CrossRefPubMedGoogle Scholar
  143. Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007). Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism, 92(11), 4254–4259.CrossRefPubMedGoogle Scholar
  144. Zitzmann, M., Faber, S., & Nieschlag, E. (2006). Association of specific symptoms and metabolic risks with serum testosterone in older men. The Journal of Clinical Endocrinology and Metabolism, 91(11), 4335–4343.CrossRefPubMedGoogle Scholar
  145. Zitzmann, M., Mattern, A., Hanisch, J., Gooren, L., Jones, H., & Maggi, M. (2013). IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. The Journal of Sexual Medicine, 10(2), 579–588.CrossRefPubMedGoogle Scholar
  146. Zitzmann, M., Rohayem, J., Raidt, J., Kliesch, S., Kumar, N., Sitruk-Ware, R., & Nieschlag, E. (2017). Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: A randomized clinical trial. Andrologia, 5(3), 516–526.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Global Medical Affairs AndrologyBayer AGBerlinGermany
  2. 2.Gulf Medical University School of MedicineAjmanUnited Arab Emirates

Personalised recommendations